Haematologica (Mar 2010)

ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

  • Katrien Van Roosbroeck,
  • Jan Cools,
  • Daan Dierickx,
  • José Thomas,
  • Peter Vandenberghe,
  • Michel Stul,
  • Jan Delabie,
  • Chris De Wolf-Peeters,
  • Peter Marynen,
  • Iwona Wlodarska

DOI
https://doi.org/10.3324/haematol.2009.014761
Journal volume & issue
Vol. 95, no. 3

Abstract

Read online

We report 2 ALK-positive large B-cell lymphoma cases showing granular cytoplasmic and cytoplasmic/nuclear ALK immunostaining in which cryptic ALK rearrangements were identified by fluorescent in situ hybridization and molecular analysis. In the first case, the ALK-involving t(2;3)(p23;q27) masked the cryptic SEC31A-ALK fusion generated by an insertion of the 5′ end of SEC31A (4q21) upstream of the 3′ end of ALK. This rearrangement was associated with loss of the 5′ end of ALK and duplication of SEC31A-ALK on der(20). In the second case with complex rearrangements of both chromosomes 2, a submicroscopic NPM1-ALK fusion created by insertion of the 3′ end of ALK into the NPM1 locus was evidenced. Further studies of SEC31A-ALK showed that this variant fusion transforms IL3-dependent Ba/F3 cells to growth factor independence, and that the ALK inhibitor TAE-684 reduces cell proliferation and kinase activity of SEC31A-ALK and its downstream effectors ERK1/2, AKT, STAT3 and STAT5.